)
)
)
Madera Therapeutics
Madera Therapeutics is the pioneer and leader in ClpP agonist drug development, having recognized and operationalized this novel mitochondrial target years before it was clinically validated. Madera has built the field’s most comprehensive global patent estate covering potent, next-generation ClpP agonists with activity across drug-resistant and refractory cancers. The biology and chemistry underlying these agents are supported by multiple peer-reviewed publications from leading academic groups and the U.S. National Cancer Institute, which is advancing Madera-derived compounds toward clinical evaluation.
Address
CaryNorth Carolina
United States
)
){kind=logo}
)
){kind=logo}
){kind=logo}
)
)
)
)